NVCT250117C2500
- 3.00
- 0.000.00%
Nuvectis Pharma Newsroom
Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug
S&P 500 Moves Lower; US Crude Oil Inventories Increase
Dow Falls Over 100 Points; US Producer Prices Rise In October
H.C. Wainwright Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Maintains Target Price $21
Positive Outlook for Nuvectis Pharma: Promising Clinical and Preclinical Developments Justify Buy Rating
Nuvectis Pharma Stock Plummets on Updated Data for Ovarian Cancer Study
US Stocks Edge Lower; Cisco Earnings Top Views
Nuvectis Pharma Says Trial of Cancer Drug NXP800 Demonstrates Tumor Shrinkage
Wall Street Set to Open Flat Thursday; Initial Jobless Claims Lower Than Forecast
Nuvectis Pharma Shares Are Trading Lower. The Company Reported Data From Its Phase 1b Study Evaluating NXP800.
Express News | Nuvectis Pharma Inc - Additional Phase 1B Clinical Data Expected in Q2 2025
Express News | Nuvectis Pharma Reports Encouraging Nxp800 Interim Data Supporting Ongoing Enrollment in Phase 1B Study in Patients With Platinum-Resistant Arid1a-Mutated Ovarian Cancer
Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients With Platinum-Resistant ARID1a-Mutated Ovarian Cancer
Nuvectis Pharma Gains 69%, Insider Trades Reap Benefit
Nuvectis Pharma GAAP EPS of -$0.24 Beats by $0.01
Nuvectis Pharma | 10-Q: Q3 2024 Earnings Report
Nuvectis Pharma | 8-K: Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights
Nuvectis Pharma 3Q Loss/Shr 24c >NVCT